Evolent Health Inc. (NYSE:EVH) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $23.95 and last traded at $23.42, with a volume of 145,666 shares trading hands. The stock had previously closed at $23.15.

A number of research firms have recently commented on EVH. Canaccord Genuity reaffirmed a “buy” rating on shares of Evolent Health in a research note on Thursday, May 26th. Leerink Swann reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Evolent Health in a research note on Sunday, July 17th. Zacks Investment Research raised shares of Evolent Health from a “sell” rating to a “hold” rating in a research note on Wednesday, May 18th. Finally, FBR & Co upped their price objective on shares of Evolent Health from $16.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, July 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $21.00.

The stock has a market capitalization of $1.38 billion and a price-to-earnings ratio of 6.14. The stock has a 50 day moving average price of $18.47 and a 200 day moving average price of $12.96.

Evolent Health (NYSE:EVH) last announced its earnings results on Thursday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. The firm had revenue of $49.50 million for the quarter, compared to the consensus estimate of $47.40 million. The firm’s quarterly revenue was up 33.8% compared to the same quarter last year. On average, equities analysts expect that Evolent Health Inc. will post ($0.62) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Evolent Health stock. Schroder Investment Management Group raised its stake in Evolent Health Inc. (NYSE:EVH) by 120.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 355,922 shares of the company’s stock after buying an additional 194,222 shares during the period. Schroder Investment Management Group owned approximately 0.60% of Evolent Health worth $4,310,000 as of its most recent filing with the SEC.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.